Study provides molecular rationale for combining targeted agents to treat breast cancer

Jan 14, 2011

A new study by Ohio State University cancer researchers provides a rational for treating breast cancer by combining two kinds of targeted agents, one that inhibits an overactive, cancer-causing pathway in cancer cells and one that reverses changes that silence genes that normally prevent cancer. Both types of agents are currently available and being evaluated individually in clinical trials, the researchers note.

The findings, published online in the journal Cancer Research, show that abnormal activation of the PI3K/AKT signaling pathway leads to the silencing of a number of tumor-suppressor genes that regulate cell proliferation, survival and motility and angiogenesis.

The laboratory and animal study also shows that combining an agent that inhibits PI3K and a drug that reverse the epigenetic changes that cause gene silencing significantly slows .

"The link we have uncovered between PI3K/AKT signaling and epigenetic silencing offers a new therapeutic strategy for breast cancer that combines a /AKT inhibitor and agents that target epigenetic changes," says study leader Tim H-M Huang, professor of , immunology and medical genetics at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

"Our studies show that, in models, these agents work together synergistically to reverse gene silencing and suppress cancer-cell growth, suggesting that combining these targeted agents might improve breast-cancer therapy."

Cancer development typically involves the abnormal activation of genes that regulate cell growth and the silencing of genes that normally prevent cancer development. The activation of one or more "oncogenes" and the silencing of tumor-suppressor genes are usually considered separate events that together lead to cancer. This and earlier studies led by Huang show that the two events are sometimes linked.

Huang and his colleagues are now planning a clinical trial for patients with metastatic that will investigate the use of combined targeted drugs.

Explore further: Possibilities for personalised vaccines revealed at ESMO Symposium

Provided by Ohio State University Medical Center

not rated yet
add to favorites email to friend print save as pdf

Related Stories

New suppressor of common liver cancer

Dec 15, 2009

Tumor suppressor genes make proteins that help control cell growth. Mutations in these genes that generate nonfunctional proteins can contribute to tumor development and progression. One of the most well-known tumor suppressor ...

Discovery of epigenetic memory during breast cancer

Jan 25, 2010

Researchers from the Boston University School of Medicine (BUSM) have determined how the TGFβ-Smad signaling pathway, which is over activated in late-stage cancers, is responsible for the "epigenetic memory" that maintains ...

Recommended for you

New model of follow up for breast cancer patients

3 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

4 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.